The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Live Attenuated Vaccines-Global Market Insights and Sales Trends 2024
Synopsis
An attenuated vaccine is a vaccine created by reducing the virulence of a pathogen, but still keeping it viable (or "live"). Attenuation takes an infectious agent and alters it so that it becomes harmless or less virulent. These vaccines contrast to those produced by "killing" the virus (inactivated vaccine).
The global Live Attenuated Vaccines market size is expected to reach US$ 40390 million by 2029, growing at a CAGR of 6.1% from 2023 to 2029. The market is mainly driven by the significant applications of Live Attenuated Vaccines in various end use industries. The expanding demands from the Hospitals, Clinics, Research Institutes and Others, are propelling Live Attenuated Vaccines market. Bacterial, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Viral segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Live Attenuated Vaccines, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Live Attenuated Vaccines market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Live Attenuated Vaccines market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Live Attenuated Vaccines sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Live Attenuated Vaccines covered in this report include GlaxoSmithKline, Merck, Pfizer, Astellas Pharma, Johnson & Johnson, CSL, Sanofi and Serum Institute Of India, etc.
The global Live Attenuated Vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
GlaxoSmithKline
Merck
Pfizer
Astellas Pharma
Johnson & Johnson
CSL
Sanofi
Serum Institute Of India
Global Live Attenuated Vaccines market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Live Attenuated Vaccines market, Segment by Type:
Bacterial
Viral
Global Live Attenuated Vaccines market, by Application
Hospitals
Clinics
Research Institutes
Others
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Live Attenuated Vaccines manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Live Attenuated Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
An attenuated vaccine is a vaccine created by reducing the virulence of a pathogen, but still keeping it viable (or "live"). Attenuation takes an infectious agent and alters it so that it becomes harmless or less virulent. These vaccines contrast to those produced by "killing" the virus (inactivated vaccine).
The global Live Attenuated Vaccines market size is expected to reach US$ 40390 million by 2029, growing at a CAGR of 6.1% from 2023 to 2029. The market is mainly driven by the significant applications of Live Attenuated Vaccines in various end use industries. The expanding demands from the Hospitals, Clinics, Research Institutes and Others, are propelling Live Attenuated Vaccines market. Bacterial, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Viral segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Live Attenuated Vaccines, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Live Attenuated Vaccines market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Live Attenuated Vaccines market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Live Attenuated Vaccines sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Live Attenuated Vaccines covered in this report include GlaxoSmithKline, Merck, Pfizer, Astellas Pharma, Johnson & Johnson, CSL, Sanofi and Serum Institute Of India, etc.
The global Live Attenuated Vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
GlaxoSmithKline
Merck
Pfizer
Astellas Pharma
Johnson & Johnson
CSL
Sanofi
Serum Institute Of India
Global Live Attenuated Vaccines market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Live Attenuated Vaccines market, Segment by Type:
Bacterial
Viral
Global Live Attenuated Vaccines market, by Application
Hospitals
Clinics
Research Institutes
Others
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Live Attenuated Vaccines manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Live Attenuated Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Live Attenuated Vaccines Market Overview
1.1 Live Attenuated Vaccines Product Overview
1.2 Live Attenuated Vaccines Market Segment by Type
1.2.1 Bacterial
1.2.2 Viral
1.3 Global Live Attenuated Vaccines Market Size by Type
1.3.1 Global Live Attenuated Vaccines Market Size Overview by Type (2018-2029)
1.3.2 Global Live Attenuated Vaccines Historic Market Size Review by Type (2018-2023)
1.3.3 Global Live Attenuated Vaccines Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Live Attenuated Vaccines Sales Breakdown by Type (2018-2023)
1.4.2 Europe Live Attenuated Vaccines Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Live Attenuated Vaccines Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Live Attenuated Vaccines Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Live Attenuated Vaccines Sales Breakdown by Type (2018-2023)
2 Global Live Attenuated Vaccines Market Competition by Company
2.1 Global Top Players by Live Attenuated Vaccines Sales (2018-2023)
2.2 Global Top Players by Live Attenuated Vaccines Revenue (2018-2023)
2.3 Global Top Players by Live Attenuated Vaccines Price (2018-2023)
2.4 Global Top Manufacturers Live Attenuated Vaccines Manufacturing Base Distribution, Sales Area, Product Type
2.5 Live Attenuated Vaccines Market Competitive Situation and Trends
2.5.1 Live Attenuated Vaccines Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Live Attenuated Vaccines Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Live Attenuated Vaccines as of 2022)
2.7 Date of Key Manufacturers Enter into Live Attenuated Vaccines Market
2.8 Key Manufacturers Live Attenuated Vaccines Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Live Attenuated Vaccines Status and Outlook by Region
3.1 Global Live Attenuated Vaccines Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Live Attenuated Vaccines Historic Market Size by Region
3.2.1 Global Live Attenuated Vaccines Sales in Volume by Region (2018-2023)
3.2.2 Global Live Attenuated Vaccines Sales in Value by Region (2018-2023)
3.2.3 Global Live Attenuated Vaccines Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Live Attenuated Vaccines Forecasted Market Size by Region
3.3.1 Global Live Attenuated Vaccines Sales in Volume by Region (2024-2029)
3.3.2 Global Live Attenuated Vaccines Sales in Value by Region (2024-2029)
3.3.3 Global Live Attenuated Vaccines Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Live Attenuated Vaccines by Application
4.1 Live Attenuated Vaccines Market Segment by Application
4.1.1 Hospitals
4.1.2 Clinics
4.1.3 Research Institutes
4.1.4 Others
4.2 Global Live Attenuated Vaccines Market Size by Application
4.2.1 Global Live Attenuated Vaccines Market Size Overview by Application (2018-2029)
4.2.2 Global Live Attenuated Vaccines Historic Market Size Review by Application (2018-2023)
4.2.3 Global Live Attenuated Vaccines Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Live Attenuated Vaccines Sales Breakdown by Application (2018-2023)
4.3.2 Europe Live Attenuated Vaccines Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Live Attenuated Vaccines Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Live Attenuated Vaccines Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Live Attenuated Vaccines Sales Breakdown by Application (2018-2023)
5 North America Live Attenuated Vaccines by Country
5.1 North America Live Attenuated Vaccines Historic Market Size by Country
5.1.1 North America Live Attenuated Vaccines Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Live Attenuated Vaccines Sales in Volume by Country (2018-2023)
5.1.3 North America Live Attenuated Vaccines Sales in Value by Country (2018-2023)
5.2 North America Live Attenuated Vaccines Forecasted Market Size by Country
5.2.1 North America Live Attenuated Vaccines Sales in Volume by Country (2024-2029)
5.2.2 North America Live Attenuated Vaccines Sales in Value by Country (2024-2029)
6 Europe Live Attenuated Vaccines by Country
6.1 Europe Live Attenuated Vaccines Historic Market Size by Country
6.1.1 Europe Live Attenuated Vaccines Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Live Attenuated Vaccines Sales in Volume by Country (2018-2023)
6.1.3 Europe Live Attenuated Vaccines Sales in Value by Country (2018-2023)
6.2 Europe Live Attenuated Vaccines Forecasted Market Size by Country
6.2.1 Europe Live Attenuated Vaccines Sales in Volume by Country (2024-2029)
6.2.2 Europe Live Attenuated Vaccines Sales in Value by Country (2024-2029)
7 Asia-Pacific Live Attenuated Vaccines by Region
7.1 Asia-Pacific Live Attenuated Vaccines Historic Market Size by Region
7.1.1 Asia-Pacific Live Attenuated Vaccines Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Live Attenuated Vaccines Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Live Attenuated Vaccines Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Live Attenuated Vaccines Forecasted Market Size by Region
7.2.1 Asia-Pacific Live Attenuated Vaccines Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Live Attenuated Vaccines Sales in Value by Region (2024-2029)
8 Latin America Live Attenuated Vaccines by Country
8.1 Latin America Live Attenuated Vaccines Historic Market Size by Country
8.1.1 Latin America Live Attenuated Vaccines Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Live Attenuated Vaccines Sales in Volume by Country (2018-2023)
8.1.3 Latin America Live Attenuated Vaccines Sales in Value by Country (2018-2023)
8.2 Latin America Live Attenuated Vaccines Forecasted Market Size by Country
8.2.1 Latin America Live Attenuated Vaccines Sales in Volume by Country (2024-2029)
8.2.2 Latin America Live Attenuated Vaccines Sales in Value by Country (2024-2029)
9 Middle East and Africa Live Attenuated Vaccines by Country
9.1 Middle East and Africa Live Attenuated Vaccines Historic Market Size by Country
9.1.1 Middle East and Africa Live Attenuated Vaccines Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Live Attenuated Vaccines Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Live Attenuated Vaccines Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Live Attenuated Vaccines Forecasted Market Size by Country
9.2.1 Middle East and Africa Live Attenuated Vaccines Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Live Attenuated Vaccines Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 GlaxoSmithKline
10.1.1 GlaxoSmithKline Company Information
10.1.2 GlaxoSmithKline Introduction and Business Overview
10.1.3 GlaxoSmithKline Live Attenuated Vaccines Sales, Revenue and Gross Margin (2018-2023)
10.1.4 GlaxoSmithKline Live Attenuated Vaccines Products Offered
10.1.5 GlaxoSmithKline Recent Development
10.2 Merck
10.2.1 Merck Company Information
10.2.2 Merck Introduction and Business Overview
10.2.3 Merck Live Attenuated Vaccines Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Merck Live Attenuated Vaccines Products Offered
10.2.5 Merck Recent Development
10.3 Pfizer
10.3.1 Pfizer Company Information
10.3.2 Pfizer Introduction and Business Overview
10.3.3 Pfizer Live Attenuated Vaccines Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Pfizer Live Attenuated Vaccines Products Offered
10.3.5 Pfizer Recent Development
10.4 Astellas Pharma
10.4.1 Astellas Pharma Company Information
10.4.2 Astellas Pharma Introduction and Business Overview
10.4.3 Astellas Pharma Live Attenuated Vaccines Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Astellas Pharma Live Attenuated Vaccines Products Offered
10.4.5 Astellas Pharma Recent Development
10.5 Johnson & Johnson
10.5.1 Johnson & Johnson Company Information
10.5.2 Johnson & Johnson Introduction and Business Overview
10.5.3 Johnson & Johnson Live Attenuated Vaccines Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Johnson & Johnson Live Attenuated Vaccines Products Offered
10.5.5 Johnson & Johnson Recent Development
10.6 CSL
10.6.1 CSL Company Information
10.6.2 CSL Introduction and Business Overview
10.6.3 CSL Live Attenuated Vaccines Sales, Revenue and Gross Margin (2018-2023)
10.6.4 CSL Live Attenuated Vaccines Products Offered
10.6.5 CSL Recent Development
10.7 Sanofi
10.7.1 Sanofi Company Information
10.7.2 Sanofi Introduction and Business Overview
10.7.3 Sanofi Live Attenuated Vaccines Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Sanofi Live Attenuated Vaccines Products Offered
10.7.5 Sanofi Recent Development
10.8 Serum Institute Of India
10.8.1 Serum Institute Of India Company Information
10.8.2 Serum Institute Of India Introduction and Business Overview
10.8.3 Serum Institute Of India Live Attenuated Vaccines Sales, Revenue and Gross Margin (2018-2023)
10.8.4 Serum Institute Of India Live Attenuated Vaccines Products Offered
10.8.5 Serum Institute Of India Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Live Attenuated Vaccines Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Live Attenuated Vaccines Industrial Chain Analysis
11.4 Live Attenuated Vaccines Market Dynamics
11.4.1 Live Attenuated Vaccines Industry Trends
11.4.2 Live Attenuated Vaccines Market Drivers
11.4.3 Live Attenuated Vaccines Market Challenges
11.4.4 Live Attenuated Vaccines Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Live Attenuated Vaccines Distributors
12.3 Live Attenuated Vaccines Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
